Palliative Chemotherapy for Pancreatic Adenocarcinoma: a Retrospective Cohort Analysis of Efficacy and Toxicity of the FOLFIRINOX Regimen Focusing on the Older Patient

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2017 Dec 7

PMID 29207968

Citations 12

Authors

Anne Katrin Berger

Georg Martin Haag

Martin Ehmann

Anne Byl

Dirk Jager

Christoph Springfeld

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer occurs more frequently in older patients, but these are underrepresented in the phase III clinical studies that established the current treatment standards. This leads to uncertainty regarding the treatment of older patients with potentially toxic but active regimens like FOLFIRINOX.

Methods: We conducted a retrospective analysis of patients treated according to the FOLFIRINOX protocol at our institution between 2010 and 2014 with a focus on older patients.

Results: Overall survival in our cohort was 10.2 months. Only 43% of patients did not need dose adaptations, but dose reductions did not lead to an inferior survival. We did not find evidence that patients aged 65 years and older deemed fit enough for palliative treatment had more toxicities or a worse outcome than younger patients.

Conclusion: We conclude that treatment with the FOLFIRINOX protocol in patients with pancreatic cancer should not be withhold from patients solely based on their chronological age but rather be based on the patient's performance status and comorbidities.

Citing Articles

Extracellular Signal-Regulated Kinase Inhibitor SCH772984 Augments the Anti-Cancer Effects of Gemcitabine in Nanoparticle Form in Pancreatic Cancer Models.

Nair G, Linster E, Ray P, Quadir M, Reindl K Int J Mol Cell Med. 2024; 13(3):220-233.

PMID: 39493509 PMC: 11530947. DOI: 10.22088/IJMCM.BUMS.13.3.220.

Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas.

Domagala-Haduch M, Robek A, Wnuk J, Michalecki L, Gisterek I Contemp Oncol (Pozn). 2023; 27(1):10-13.

PMID: 37266343 PMC: 10230235. DOI: 10.5114/wo.2023.127013.

Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer.

Kwan B, Lee O, Kim H, Kim K, Shim S, Cho D J Clin Med. 2023; 12(9).

PMID: 37176774 PMC: 10178943. DOI: 10.3390/jcm12093334.

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine.

Di Costanzo F, Di Costanzo F, Antonuzzo L, Mazza E, Giommoni E Cancers (Basel). 2023; 15(2).

PMID: 36672366 PMC: 9856679. DOI: 10.3390/cancers15020416.

Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database.

Conti C, Pamoukdjian F, Aparicio T, Mebarki S, Poisson J, Manceau G Cancers (Basel). 2022; 14(5).

PMID: 35267412 PMC: 8909682. DOI: 10.3390/cancers14051105.

References

Kumar A, Soares H, Balducci L, Djulbegovic B . Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol. 2007; 25(10):1272-6. DOI: 10.1200/JCO.2006.09.2759. View

Pallis A, Fortpied C, Wedding U, Van Nes M, Penninckx B, Ring A . EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010; 46(9):1502-13. DOI: 10.1016/j.ejca.2010.02.022. View

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

Hidalgo M . Pancreatic cancer. N Engl J Med. 2010; 362(17):1605-17. DOI: 10.1056/NEJMra0901557. View

Peddi P, Lubner S, McWilliams R, Tan B, Picus J, Sorscher S . Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012; 13(5):497-501. DOI: 10.6092/1590-8577/913. View

Blazer M, Wu C, Goldberg R, Phillips G, Schmidt C, Muscarella P . Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2014; 22(4):1153-9. PMC: 4373613. DOI: 10.1245/s10434-014-4225-1. View

Goldstein D, El-Maraghi R, Hammel P, Heinemann V, Kunzmann V, Sastre J . nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015; 107(2). DOI: 10.1093/jnci/dju413. View

Yancik R . Population aging and cancer: a cross-national concern. Cancer J. 2006; 11(6):437-41. DOI: 10.1097/00130404-200511000-00002. View

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

10.

Gunturu K, Yao X, Cong X, Thumar J, Hochster H, Stein S . FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2012; 30(1):361. DOI: 10.1007/s12032-012-0361-2. View

11.

Werner J, Combs S, Springfeld C, Hartwig W, Hackert T, Buchler M . Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013; 10(6):323-33. DOI: 10.1038/nrclinonc.2013.66. View

12.

Ko A . FOLFIRINOX: a small step or a great leap forward?. J Clin Oncol. 2011; 29(28):3727-9. DOI: 10.1200/JCO.2011.37.3464. View

13.

Vincent A, Herman J, Schulick R, Hruban R, Goggins M . Pancreatic cancer. Lancet. 2011; 378(9791):607-20. PMC: 3062508. DOI: 10.1016/S0140-6736(10)62307-0. View

14.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

15.

NIEDERHUBER J, Brennan M, Menck H . The National Cancer Data Base report on pancreatic cancer. Cancer. 1995; 76(9):1671-7. DOI: 10.1002/1097-0142(19951101)76:9<1671::aid-cncr2820760926>3.0.co;2-r. View

16.

Kim Y, Hui D, Zhang Y, Park J, Chisholm G, Williams J . Differences in Performance Status Assessment Among Palliative Care Specialists, Nurses, and Medical Oncologists. J Pain Symptom Manage. 2014; 49(6):1050-1058.e2. DOI: 10.1016/j.jpainsymman.2014.10.015. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

19.

Weir H, Thompson T, Soman A, Moller B, Leadbetter S . The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer. 2015; 121(11):1827-37. PMC: 4507799. DOI: 10.1002/cncr.29258. View

20.

Berger A, Zschaebitz S, Komander C, Jager D, Haag G . Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. World J Gastroenterol. 2015; 21(16):4911-8. PMC: 4408463. DOI: 10.3748/wjg.v21.i16.4911. View